Cardiovascular Risk
2
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 4 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs2
ZiltivekimabPhase 3Monoclonal Antibody1 trial
Ziltivekimab BPhase 31 trial
No treatment givenN/A1 trial
Active Trials
AstraZenecaCAMBRIDGE, United Kingdom
1 programLevel of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular RiskN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Novo NordiskZiltivekimab
Novo NordiskZiltivekimab B
Beacon TherapeuticsPlant Omega
Novo NordiskNo treatment given
AstraZenecaLevel of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk
Clinical Trials (5)
Total enrollment: 35,197 patients across 5 trials
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Start: Jun 2024Est. completion: Sep 202610,000 patients
Phase 3Recruiting
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Start: Aug 2021Est. completion: Jun 20266,200 patients
Phase 3Active Not Recruiting
The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals with Cardiovascular(CVD) Risk
Start: Dec 2024Est. completion: Dec 2025
N/ANot Yet Recruiting
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
Start: Nov 2023Est. completion: Apr 202518,198 patients
N/ACompleted
NCT01781416AstraZenecaLevel of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk
Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk
Start: Nov 2013Est. completion: Apr 2014799 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 35,197 patients
3 companies competing in this space